Additionally, it is important to consider that aggressive cancers such as MYC-amplified Group 3 MB have a strong capacity to develop therapy evasion mechanisms and resistance when confronted with highly cytotoxic multimodal chemotherapy [17]. The gene discussed is MYC; the disease is cancer.